Featuring an interview with Dr Rafael Fonseca, including the following topics:
- Safe management of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma (MM) (0:00)
- Sequencing bispecific antibodies and CAR T-cell therapy (10:40)
- Available data with and potential future clinical integration of belantamab mafodotin in the management of MM (16:03)
- Optimizing maintenance therapy for patients with MM (31:11)
- Novel management strategies for smoldering myeloma (36:29)
- Role of anti-CD38 antibodies in the up-front management of MM (41:41)
- Available data with cereblon E3 ligase modulatory drugs for MM (47:45)